On August 16, 2019, FDA approved transcatheter aortic valve replacement (TAVR) in severe aortic stenosis patients at low-risk for surgery. This was a highly-anticipated move following the compelling results of low-risk TAVR trials presented earlier this year at the American College of Cardiology Scientific Session. Unlike previous indication expansions, FDA approved both the Medtronic and Edwards valves at once.